Advertisement

Clinical Pharmacokinetics

, Volume 25, Issue 3, pp 165–171 | Cite as

Advantages and Disadvantages of Reformulation of Older Drugs

  • Berend Oosterhuis
  • Jan H. G. Jonkman
Leading Article

Keywords

Theophylline German Market Control Release Formulation Oinical Pharmacology Gonadorelin 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. CPMP Working Party on Efficacy of Medicinal Products. Investigation of Bioavailability and Bioequivalence. Note for Guidance III/54/89-EN, December, 1991Google Scholar
  2. Cramer JA, Mattson RH, Prevey ML, Scheyer RD, Valinda L, et al. How often is medication taken as prescribed? Journal of the American Medical Association 261: 2373–2377, 1989CrossRefGoogle Scholar
  3. Fletcher A, McLoone P, Bulpitt C. Quality of life on angina therapy: a randomised controlled trial of transdermal glyceryl trinitrate against placebo. Lancet 2: 4–7, 1988PubMedCrossRefGoogle Scholar
  4. Greenberg RN. Overview of patient compliance with medication dosing: a literature review. Clinical Therapeutics 6: 592–599, 1984PubMedGoogle Scholar
  5. Jonkman JHG. Food interactions with sustained release theophylline preparations. Clinical Pharmacokinetics 16: 162–179, 1989PubMedCrossRefGoogle Scholar
  6. Kleinbloesem CH, Van Brummelen P, Danhof M, Faber H, Urquhart J, et al. Rate of increase in the plasma concentration of nifedipine as a major determinant of its hemodynamic effects in humans. Clinical Pharmacology and Therapeutics 41: 26–30, 1987PubMedCrossRefGoogle Scholar
  7. Kleinbloesem CH, Van Brummelen P, Van de Linde JA, Voogd PJ, Breimer DD. Nifedipine: kinetics and dynamics in healthy subjects. Clinical Pharmacology and Therapeutics 35: 742–749, 1984PubMedCrossRefGoogle Scholar
  8. Leeuwenkamp OR, Visscher HW, Mensink CK, Jonkman JHG. A comparative study of the steady state pharmacokinetics of immediate-release and controlled-release diltiazem tablets. European Journal of Clinical Pharmacology, in press, 1993Google Scholar
  9. Manninen V, Melin H, Hartel G. Serum-digoxin concentrations during treatment with different preparations. Lancet 2: 934–935, 1971PubMedCrossRefGoogle Scholar
  10. Oosterhuis B, Jonkman JHG. Significance of the reference product in bioequivalence evaluations with highly variable drugs: pharmaceutical quality, variability, biopharmaceutical characteristics. In Blume & Midha (Eds) Bio-international’ 92: bioavailability, bioequivalence and pharmacokinetic studies, Medpharm Scientific Publishers, Stuttgart, in press, 1993Google Scholar
  11. Prescott LF, Nimmo WS (Eds) Novel drug delivery, pp. 1–11, John Wiley & Sons, Chichester, 1989Google Scholar
  12. Rawlins MD. Adverse effects of novel delivery systems. In Prescott & Nimmo (Eds) Novel drug delivery, pp. 237–244, John Wiley & Sons, Chichester, 1989Google Scholar
  13. Reynolds JEF (Ed.) Martindale: the extra pharmacopoeia, 27th ed., Pharmaceutical Press, London, 1977Google Scholar
  14. Rocco MB, Barry S, Cambell S. Circadian variation of transient myocardial ischemia in patients with coronary artery disease. Circulation 75: 395–400, 1987PubMedCrossRefGoogle Scholar
  15. Skelly JP. Drug regulation and novel drug delivery systems. In Prescott & Nimmo (Eds) Novel drug delivery, pp. 341–351, John Wiley & Sons, Chichester, 1989Google Scholar
  16. Steinijans VW, Sauter R, Böhm A, Staudiger H. Pharmacokinetic profile of a new sustained-release theophylline pellet formulation for once-daily evening administration. Arzneimittel-Forschung 38(2): 1241–1250, 1988PubMedGoogle Scholar
  17. Stewart RB, Cluff LE. A review of medication errors and compliance in ambulant patients. Clinical Pharmacology and Therapeutics 13: 463–468, 1972PubMedGoogle Scholar
  18. Strieker H. Superbioavailability. In Blume & Midha (Eds) Biointernational’ 92: bioavailability, bioequivalence and pharmacokinetic studies, Medpharm Scientific Publishers, Stuttgart, in press, 1993Google Scholar
  19. Urquhart J. Time to take our medicines seriously. Pharmaceutisch Weekblad - Scientific Edition 127: 769–776, 1992Google Scholar
  20. Urquhart J, Chevalley C. Impact of unrecognized dosing errors on the cost and effectiveness of pharmaceuticals. Drug Information Journal 22: 363–378, 1988Google Scholar
  21. Welling PG, Tse FLS, Dighe SV (Eds). Pharmaceutical bioequivalence, pp. 347–461, Marcel Dekker Inc., New York, 1991Google Scholar
  22. Wendt G. Marktübersicht zu Bioäquivalenzangaben von Theophyllin-retardpräparaten in Deutschland. In Blume & Krämer (Eds) Bioäquivalenzbewertung retardierter Theophyllin-fertig-arzneimittel, pp. 39–50, Govi Verlag, Frankfurt, 1990Google Scholar

Copyright information

© Adis International Limited 1993

Authors and Affiliations

  • Berend Oosterhuis
    • 1
  • Jan H. G. Jonkman
    • 1
  1. 1.Pharma Bio-Research International B.V.ZuidlarenThe Netherlands

Personalised recommendations